Novartis AG
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Sandostatin Group (octreotide by Year
Sandostatin Group (octreotide — neuroendocrine tumors & acromegaly) ($M)
Novartis Sandostatin Group (octreotide: $1,213M in FY2025, down 5.2% from a year earlier. That is the lowest of the 9 years on record here.
Where the FY2025 figure comes from
“|| Sandostatin Group | 1 213 | 1 279 | -5 | -5”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Sandostatin Group (octreotide — neuroendocrine tumors & acromegaly) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,213 | -5.2% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 1,279 | -2.7% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 1,314 | +6.1% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 1,238 | -12.4% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 1,413 | -1.8% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 1,439 | -9.2% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 1,585 | -0.1% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2018 | Dec 31, 2018 | 1,587 | -1.6% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2017 | Dec 31, 2017 | 1,612 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up sandostatin Group (octreotide
Cite this data
StockData. (2026). Novartis Sandostatin Group (octreotide ($M), annual FY2017–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-sandostatin-group
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.